Antidepressants for polycystic ovary syndrome

  • Review
  • Intervention

Authors

  • Jing Zhuang,

    1. West China Second Hospital, Sichuan University, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China
    Search for more papers by this author
  • Xianding Wang,

    1. West China Hospital, Sichuan University, Department of Urology, Chengdu, Sichuan, China
    Search for more papers by this author
  • Liangzhi Xu,

    Corresponding author
    1. West China Second University Hospital, West China Women's and Children's Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China
    • Liangzhi Xu, Department of Obstetrics and Gynecology, West China Second University Hospital, West China Women's and Children's Hospital, No. 20, Section Three, Ren Min Nan Lu Avenue, Chengdu, Sichuan, 610041, China. liangzxu@126.com.

    Search for more papers by this author
  • Taixiang Wu,

    1. West China Hospital, Sichuan University, Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials, Chengdu, Sichuan, China
    Search for more papers by this author
  • Deying Kang

    1. West China Hospital, Sichuan University, Department of Clinical Epidemiology, Chengdu, Sichuan, China
    Search for more papers by this author

Abstract

Background

The prevalence of depression in women with polycystic ovary syndrome (PCOS) is high; one study has shown it to be four times that of women without PCOS. Therefore, systematic evaluation of the effectiveness and safety of antidepressants for women with PCOS is important.

Objectives

To evaluate the effectiveness and safety of antidepressants in treating depression and other symptoms in women with PCOS.

Search methods

We searched the following databases from inception to June 2012: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, PsycINFO and Chinese National Knowledge Infrastructure, the metaRegister of Controlled Trials (controlled-trials.com), the National Institute of Health Clinical Trials register (clinicaltrials.gov) and the World Health Organization International Trials Registry Platform search portal (www.who.int/trialsearch/Default.aspx).

Selection criteria

Only randomised controlled trials (RCTs) studying the effectiveness and safety of antidepressants for women with PCOS were included in this review.

Data collection and analysis

The methodological quality of the trials was assessed independently by two review authors, in parallel with data extraction. The risk of bias in the included study was assessed in six domains: 1. sequence generation; 2. allocation concealment; 3. blinding of participants, personnel and outcome assessors; 4. completeness of outcome data; 5. selective outcome reporting; 6. other potential sources of bias.

Main results

We found no studies reporting any of our primary review outcomes (depression and allied mood disorder scores, quality of life and adverse events). Only one study with 16 women was eligible for inclusion. This study compared sibutramine versus fluoxetine in women with PCOS, and reported only endocrine and metabolic outcomes. It was unclear whether the participants had psychological problems at baseline. No significant difference was found between the groups for any of the measured outcomes.

Authors' conclusions

There is no evidence on the effectiveness and safety of antidepressants in treating depression and other symptoms in women with PCOS.

Plain language summary

The effect of antidepressants for women with polycystic ovary syndrome

The prevalence of depression in women with polycystic ovary syndrome (PCOS) is high; a study has shown it to be four times that of women without PCOS. Therefore, systematic evaluation of the effectiveness and safety of antidepressants for women with PCOS is important. We found no evidence to support the use or non-use of antidepressants in women with PCOS, with or without depression. Well-designed and well-conducted randomised controlled trials with double blinding should be conducted.

Laički sažetak

Učinak antidepresiva u žena sa sindromom policističnih jajnika

Pojavnost depresije u žena sa sindromom policističnih jajnika (PCOS) je visoka; dostupni podatci pokazuju da je četiri puta češća nego kod žena koje nemaju PCOS. S obzirom na to, važna je sustavna procjena djelotvornosti i sigurnosti antidepresiva za žene s PCOS. Nisu pronađeni dokazi koji bi podržali ili pobili korištenje antidepresiva u žena s PCOS, sa ili bez depresije. Trebalo bi provesti visoko kvalitetne dvostruko slijepe randomizirane kontrolirane studije na tu temu.

Bilješke prijevoda

Hrvatski Cochrane
Preveo: Adam Galkovski
Ovaj sažetak preveden je u okviru volonterskog projekta prevođenja Cochrane sažetaka. Uključite se u projekt i pomozite nam u prevođenju brojnih preostalih Cochrane sažetaka koji su još uvijek dostupni samo na engleskom jeziku. Kontakt: cochrane_croatia@mefst.hr